Ally Bridge Group (NY) LLC — 13F Holdings & Portfolio
CIK 1822947 · latest 13F-HR filed 2026-08-14
Ally Bridge Group (NY) LLC manages $113.1M in 13F-reported U.S. long-equity assets across 25 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are DFTX (16.64%), ABVX (14.73%), NERV (10.68%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 10 new positions and exited 8; 4 existing positions rose in reported value and 9 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 64.8%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 31, 2026.
12TH FLOOR
NEW YORK, NY 10022
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| ABG MANAGEMENT LTD Control | SHAREHOLDER since Mar 2017 | 75% or more | Foreign Entity |
| ALEX, SLANIX PAUL, T Control | PRESIDENT & PORTFOLIO MANAGER since Jan 2023 | Less than 5% | Individual |
| BENDETSON, MICHAEL, NOVICK Control | COO, HEAD OF LEGAL & CHIEF COMPLIANCE OFFICER since Feb 2021 | Less than 5% | Individual |
| CORB, KEVIN, WILLIAM Control | CHIEF FINANCIAL OFFICER since Feb 2023 | Less than 5% | Individual |
| YU, FAN Control Indirect owner via ABG MANAGEMENT LTD | SHAREHOLDER AND DIRECTOR since Jun 2013 | 75% or more | Individual |
Ownership & leadership changes · 4 filings with changes since Jun 30, 2021
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- ChangedALEX, SLANIX PAUL, T · title PORTFOLIO MANAGER → PRESIDENT & PORTFOLIO MANAGER
- No longer listedJOHNSON, DANIEL, JOHN · CHIEF FINANCIAL OFFICER · Less than 5% · control person · listed since Jul 2020
- No longer listedSIMEONIDIS, SIMOS, EFTHYMIOS · PRESIDENT AND PORTFOLIO MANAGER · Less than 5% · control person · listed since Jul 2022
- AddedALEX, SLANIX PAUL, T · PORTFOLIO MANAGER · Less than 5% · control person
- AddedCORB, KEVIN, WILLIAM · CHIEF FINANCIAL OFFICER · Less than 5% · control person
- ChangedBENDETSON, MICHAEL, NOVICK · title HEAD OF LEGAL & CHIEF COMPLIANCE OFFICER → COO, HEAD OF LEGAL & CHIEF COMPLIANCE OFFICER
- No longer listedYAEGER, ANNA, COSSLETT · PORTFOLIO MANAGER AND PRESIDENT · Less than 5% · control person · listed since Jul 2017
- AddedSIMEONIDIS, SIMOS, EFTHYMIOS · PRESIDENT AND PORTFOLIO MANAGER · Less than 5% · control person
- ChangedBENDETSON, MICHAEL, NOVICK · title DIRECTOR OF LEGAL & COMPLIANCE, CHIEF COMPLIANCE OFFICER → HEAD OF LEGAL & CHIEF COMPLIANCE OFFICER
- ListedABG MANAGEMENT LTD · SHAREHOLDER · 75% or more · control person
- ListedBENDETSON, MICHAEL, NOVICK · DIRECTOR OF LEGAL & COMPLIANCE, CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- ListedJOHNSON, DANIEL, JOHN · CHIEF FINANCIAL OFFICER · Less than 5% · control person
- ListedYAEGER, ANNA, COSSLETT · PORTFOLIO MANAGER AND PRESIDENT · Less than 5% · control person
- ListedYU, FAN · SHAREHOLDER AND DIRECTOR · 75% or more · indirect via ABG MANAGEMENT LTD · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- PROMIS NEUROSCIENCES INC$2.9M +55.2%
- MINERVA NEUROSCIENCES INC$2.1M +21.1%
- WHITEHAWK THERAPEUTICS INC$924.3K +32.8%
- AN2 THERAPEUTICS INC$747.4K +41.5%
Top Trims
- OVID THERAPEUTICS INC-$4.6M -73.1%
- EUPRAXIA PHARMACEUTICALS INC-$3.1M -65.1%
- SOLID BIOSCIENCES INC-$3.0M -53.7%
- INVENTIVA SA-$1.7M -42.0%
- EDGEWISE THERAPEUTICS INC-$1.7M -33.3%
New Positions
- FIRST TRACKS BIOTHERAPEUTICS$5.7M
- AXSOME THERAPEUTICS INC$4.0M
- ASSEMBLY BIOSCIENCES INC$3.8M
- CLIMB BIO INC$3.2M
- KURA ONCOLOGY INC$3.2M
Exited Positions
- PRAXIS PRECISION MEDICINES I$10.6M
- SOLENO THERAPEUTICS INC$6.7M
- COMPASS PATHWAYS PLC$5.8M
- TARSUS PHARMACEUTICALS INC$5.7M
- ABIVAX SA$3.8M
Ally Bridge Group (NY) LLC Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | DEFINIUM THERAPEUTICS INC Call | DFTX | 24477V105 | $18.8M | 16.64% | 400,000 | SH |
| 2 | ABIVAX SA Call | ABVX | 00370M103 | $16.7M | 14.73% | 125,000 | SH |
| 3 | MINERVA NEUROSCIENCES INC | NERV | 603380205 | $12.1M | 10.68% | 2,175,802 | SH |
| 4 | PROMIS NEUROSCIENCES INC | PMN | 74346M505 | $8.2M | 7.22% | 620,319 | SH |
| 5 | FIRST TRACKS BIOTHERAPEUTICS | TRAX | 337185102 | $5.7M | 5.06% | 284,287 | SH |
| 6 | AXSOME THERAPEUTICS INC | AXSM | 05464T104 | $4.0M | 3.57% | 16,493 | SH |
| 7 | ASSEMBLY BIOSCIENCES INC | ASMB | 045396207 | $3.8M | 3.40% | 140,000 | SH |
| 8 | WHITEHAWK THERAPEUTICS INC | WHWK | 00032Q104 | $3.7M | 3.31% | 817,939 | SH |
| 9 | EDGEWISE THERAPEUTICS INC | EWTX | 28036F105 | $3.4M | 2.99% | 83,300 | SH |
| 10 | CLIMB BIO INC | CLYM | 28658R106 | $3.2M | 2.87% | 249,172 | SH |
| 11 | KURA ONCOLOGY INC | KURA | 50127T109 | $3.2M | 2.81% | 290,000 | SH |
| 12 | CYTOMX THERAPEUTICS INC. | CTMX | 23284F105 | $2.9M | 2.57% | 775,000 | SH |
| 13 | AVALO THERAPEUTICS INC | AVTX | 05338F306 | $2.8M | 2.45% | 150,000 | SH |
| 14 | PALISADE BIO INC | PALI | 696389402 | $2.6M | 2.27% | 1,229,000 | SH |
| 15 | SOLID BIOSCIENCES INC | SLDB | 83422E204 | $2.6M | 2.26% | 255,959 | SH |
| 16 | AN2 THERAPEUTICS INC | ANTX | 037326105 | $2.5M | 2.25% | 526,315 | SH |
| 17 | UROGEN PHARMA LTD | URGN | M96088105 | $2.5M | 2.25% | 69,183 | SH |
| 18 | PERSPECTIVE THERAPEUTICS INC | CATX | 46489V302 | $2.5M | 2.24% | 743,958 | SH |
| 19 | IDEAYA BIOSCIENCES INC | IDYA | 45166A102 | $2.5M | 2.22% | 67,500 | SH |
| 20 | INVENTIVA SA | IVA | 46124U107 | $2.4M | 2.12% | 634,800 | SH |
| 21 | ALUMIS INC | ALMS | 022307102 | $2.2M | 1.90% | 76,459 | SH |
| 22 | OVID THERAPEUTICS INC | OVID | 690469101 | $1.7M | 1.49% | 624,561 | SH |
| 23 | EUPRAXIA PHARMACEUTICALS INC | EPRX | 29842P105 | $1.7M | 1.47% | 252,175 | SH |
| 24 | IBIO INC | IBIO | 451033708 | $682.8K | 0.60% | 390,147 | SH |
| 25 | TRAWS PHARMA INC | TRAW | 68232V884 | $663.0K | 0.59% | 786,236 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $113.1M | 25 | 0001193125-26-352338 |
| 2026-03-31 | 2026-05-18 | $123.8M | 28 | 0001193125-26-227559 |
| 2025-12-31 | 2026-02-17 | $96.0M | 20 | 0001193125-26-055035 |
| 2025-09-30 | 2025-11-14 | $164.2M | 25 | 0001193125-25-283054 |
NEW YORK, NY 10022